Skip to Main Content

INFORMATION FOR

    Clemens Bergwitz, MD

    Associate Professor of Medicine (Endocrinology)
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    About

    Titles

    Associate Professor of Medicine (Endocrinology)

    Biography

    Clemens W.H. Bergwitz, MD, is an endocrinologist and Associate Professor of Medicine. In 2006, he identified the genetic defect underlying the childhood disorder Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH), and since then, he has developed a research focus on inborn errors of bone and mineral metabolism. He leads several clinical trials and his lab uses murine models of hypophosphatemia to understand better the responses of the musculoskeletal and renal systems to oral phosphate therapy. Using genome-wide RNAi screens, a more recent research interest is in trying to understand how human and other metazoan cells sense inorganic phosphate and to identify mammalian systems suitable to study identified hits. He also attends the Endocrine Consult Service at Yale New Haven Hospital and, as a member of the Yale Medical Group, sees outpatients with hypophosphatemic disorders, osteoporosis, primary hyperparathyroidism, hyperthyroidism, thyroid nodules, hypogonadism, adrenal, and general endocrine disorders.

    Appointments

    Other Departments & Organizations

    Education & Training

    Fellowship
    Massachusetts General Hospital (2006)
    Residency
    Massachusetts General Hospital (2003)
    Fellowship
    NICHD, NIH (2001)
    Residency
    Hannover Medical School (1999)
    Research Fellowship
    Massachusetts General Hospital and Harvard Medical School (1996)
    MD
    Hannover Medical School (1993)
    BA
    Wilhelm Gymnasium, Chemistry and Ancient Greek (1986)

    Research

    Overview

    Genetic causes of hypophosphatemia

    In 2006 we identified the genetic defect underlying the childhood disorder Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH). HHRH is caused by mutations in NaPi-IIc, a renal sodium-phosphate co-transporter, which is important to conserve phosphate in the kidney and when lost leads to hypophosphatemia and rickets. Our research goal is now to study the role of NaPi-IIc in human phosphate homeostasis and to understand the phenotypic variability of patients suffering from HHRH. For this purpose we are currently using mammalian and Xenopus oocyte expression systems to study the functional properties of the identified human NaPi-IIc mutations in vitro. Plan for the near future is to establish mouse models to study the role of NaPi-IIc in the development of renal stones in vivo. We also established international collaborations to look for NaPi-IIc mutations in new patients suffering from HHRH both to establish their molecular diagnosis and to carefully study their symptoms to see whether only some or all patients are at risk for developing kidney stones. In addition to HHRH I serve as the principal investigator on clinical trials for serveral other genetic skeletal disorders, including X-linked hypophosphatemia, osteogenesis imperfecta and hypophosphatasia.

    Metabolic and homeostatic effects of phosphate

    A more recent research interest is in trying to understand how human and other metazoan cells sense inorganic phosphate to explain the effects of phosphate on cell metabolism (“metabolic” sensing), how phosphate feeds back to regulate the above hormonal systems (“homeostatic” sensing) and whether the “metabolic” and the “homeostatic” sensor use the same or different signal transduction cascades.

    For this purpose we have performed a genome-wide Drosophila RNAi knockdown in collaboration with Stephanie Mohr, Liz Perkins and Norbert Perrimon, Harvard Medical School using phosphate-induced activation of MAPK (in vitro). The identified 103 genes, including 84 phosphate-specific genes are currently evaluated in life flies with assays for dietary phosphate toxicity, hemolymph phosphate and life span. Our goal in the next few years will be to identify mammalian systems suitable to study phosphate sensing, while further exploring Drosophila melanogaster as model organism. Relevant readouts for humans will be the homeostatic regulation of synthesis and secretion of PTH, 1,25-D, FGF23 by phosphate and it’s metabolic effects on life-span in genetic disorders such as familial hyperphosphatemic tumoral calcinosis (FHTC) and in chronic kidney disease.

    Medical Research Interests

    Genetic Diseases, Inborn; Nephrocalcinosis; Phosphate Transport Proteins; Phosphorus Metabolism Disorders; Rickets; Signal Transduction

    Public Health Interests

    Genetics, Genomics, Epigenetics; Metabolism

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Clemens Bergwitz's published research.

    Publications

    2024

    2023

    2022

    • X-Linked Hypophosphatemic Rickets, Treatment
      Bergwitz, C Clinical Keys X-Linked Hypophosphatemic Rickets, Treatment, Elsevier, 2022, https://www.elsevier.com/products/clinicalkey
      Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

    2021

    Clinical Trials

    Current Trials

    Academic Achievements & Community Involvement

    • activity

      Association of Osteobiology

    • activity

      Advances in Mineral Metabolism (AIMM)

    • activity

      American Society of Bone and Mineral Research (ASBMR)

    • activity

      ASBMR Annual Meeting, Washington, DC

    • activity

      Skeletal Biology Development and Disease (SBDD), NIH

    Clinical Care

    Overview

    Clemens W.H. Bergwitz, MD, is an endocrinologist at Yale Medicine who sees patients with hypophosphatemic disorders, osteoporosis, primary hyperparathyroidism, hyperthyroidism, thyroid nodules, and hypogonadism, as well as adrenal and general endocrine disorders.

    Dr. Bergwitz’s characterizes the endocrine system as the human body’s own data messaging system. “It sends information to regulate some of our body’s most critical functions,” he says. In addition to treating patients, Dr. Bergwitz conducts research on many of these conditions, and his lab has worked on projects that test various therapies for hereditary endocrine disorders. “I am really a physician-scientist. My patients inspire my research, which eventually leads back to the bedside,” he says.

    Dr. Bergwitz believes that patients should be the expert of their own illness. He strives to explain conditions and treatments in plain language so that patients not only understand their disorder, but also the biological mechanisms behind it. “I’m interested in providing my patients with the information they need to not only understand their condition, but to empower them to take good care of themselves,” he says.

    Clinical Specialties

    Endocrinology

    Fact Sheets

    Board Certifications

    • Certified Clinical Densitometrist

      Certification Organization
      The International Society for Clinical Densitometry
      Original Certification Date
      2015
    • Endocrinology Diabetes & Metabolism

      Certification Organization
      AB of Internal Medicine
      Latest Certification Date
      2016
      Original Certification Date
      2005
    • Internal Medicine

      Certification Organization
      AB of Internal Medicine
      Latest Certification Date
      2016
      Original Certification Date
      2004

    Yale Medicine News

    Get In Touch

    Contacts

    Appointment Number
    Clinic Fax Number

    Locations

    • Patient Care Locations

      Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    Events

    Jan 202510Friday
    Jan 202517Friday
    Jan 202524Friday
    Jan 202531Friday